EYSUVIS Drug Patent Profile

✉ Email this page to a colleague

When do Eysuvis patents expire, and when can generic versions of Eysuvis launch?

Eysuvis is a drug marketed by Alcon Labs Inc and is included in one NDA. There are sixteen patents protecting this drug.

This drug has eighty-four patent family members in twelve countries.

The generic ingredient in EYSUVIS is loteprednol etabonate. There are ten drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Eysuvis

A generic version of EYSUVIS was approved as loteprednol etabonate by SENTISS on April 17^th, 2019.

Try a Trial

Summary for EYSUVIS

International Patents:	84
US Patents:	16
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	1
Patent Applications:	4,910
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for EYSUVIS
What excipients (inactive ingredients) are in EYSUVIS?	EYSUVIS excipients list
DailyMed Link:	EYSUVIS at DailyMed

Drug patent expirations by year for EYSUVIS

Recent Clinical Trials for EYSUVIS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Kala Pharmaceuticals, Inc.	Phase 4
Price Vision Group	Phase 4

See all EYSUVIS clinical trials

Pharmacology for EYSUVIS

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for EYSUVIS

S01BA	Corticosteroids, plain
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for EYSUVIS

EYSUVIS is protected by sixteen US patents.

Patents protecting EYSUVIS

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER

Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT

Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: ADMINISTRATION TO THE EYE OF A PATIENT FOR TREATMENT OF DRY EYE CONDITION

Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT

Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	EYSUVIS	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	210933-001	Oct 26, 2020		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Alcon Labs Inc	EYSUVIS	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	210933-001	Oct 26, 2020		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Alcon Labs Inc	EYSUVIS	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	210933-001	Oct 26, 2020		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Alcon Labs Inc	EYSUVIS	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	210933-001	Oct 26, 2020		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			⤷ Try a Trial
Alcon Labs Inc	EYSUVIS	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	210933-001	Oct 26, 2020		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			⤷ Try a Trial
Alcon Labs Inc	EYSUVIS	loteprednol etabonate	SUSPENSION/DROPS;OPHTHALMIC	210933-001	Oct 26, 2020		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial	Y			⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for EYSUVIS

See the table below for patents covering EYSUVIS around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Japan	2018162284	複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法 (COMPOSITIONS COMPRISING MULTIPLE COATED PARTICLES, PHARMACEUTICAL COMPOSITIONS, PHARMACEUTICAL FORMULATIONS, AND METHODS OF FORMING THOSE PARTICLES)	⤷ Try a Trial
European Patent Office	3808339	NANOPARTICLES PHARMACEUTIQUES MONTRANT DU TRANSPORT MUCOSALE AMÉLIORÉ (PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT)	⤷ Try a Trial
Japan	2020200337	粘液浸透性被覆粒子、組成物、医薬組成物、医薬製剤、及びそれらの形成方法 (MUCUS-PENETRATING COATED PARTICLES, COMPOSITIONS, PHARMACEUTICAL COMPOSITIONS, PHARMACEUTICAL FORMULATIONS, AND METHODS OF FORMING THEM)	⤷ Try a Trial
Japan	6978096		⤷ Try a Trial
Chile	2014002956	Composicion farmaceutica ocular que comprende particulas recubiertas de dimension menor a 1 micron, con un nucleo que comprende etaboato de loteprednol y un recubrimiento con modificadores de superficie; y uso para tratar la inflamacion, degeneracion macular, edema macular u otro trastorno del ojo.	⤷ Try a Trial
Japan	2015519330	改善された粘膜輸送を示す医薬用ナノ粒子	⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Summary for EYSUVIS

Recent Clinical Trials for EYSUVIS

Pharmacology for EYSUVIS

Anatomical Therapeutic Chemical (ATC) Classes for EYSUVIS

Patents protecting EYSUVIS

Make Better Decisions: Try a trial or see plans & pricing